ReviewOncology letters2023
Vaginal and tumor microbiomes in gynecological cancer (Review).
Review in Oncology letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Vaginal Microbiota and Ovarian Cancer: A New Frontier in Immunomodulation and Diagnosis.Immunology · 2026Review
- Bacterial Infections Role in Gynecological Cancers Development: Narrative Review.Cancer reports (Hoboken, N.J.) · 2026Review
- The intratumoral microbiome: a review of the tumor microenvironment's fourth axis shaping anti-tumor immunity, cancer prognosis, and therapeutic response.Frontiers in immunology · 2026Review
- Uterine microbiota dynamics and new therapeutic opportunities in gynecological diseases.American journal of translational research · 2026Review
- Inflammasomes meet organoids and artificial intelligence: unraveling the complexity of gynecological inflammation.Frontiers in immunology · 2026Review
- Review
- Microbiome impacts quality of life in patients with endometrial cancer and benign gynecological conditions.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Computational microbiome pharmacology analysis elucidates the anti-cancer potential of vaginal microbes and metabolites.Frontiers in microbiology · 2025Article
- Potential role of microbiota in ovarian cancer treatment.Archives of medical science : AMS · 2025Article
- The Succession of Cervical Canal Microbiota in Endometrial Cancer and Cervical Cancer: A Clinical Metagenomics Study.International journal of women's health · 2025Article
- The microbiome in endometrial cancer: vaginal milieu matters.Frontiers in medicine · 2025Article
- Distinct cervical microbiome and metabolite profiles before and after menopause: implications for cervical cancer progression.Frontiers in cellular and infection microbiology · 2025Article
- Intratumoral microbiome of adenoid cystic carcinomas and comparison with other head and neck cancers.Scientific reports · 2024Article
- Article
- Cervicovaginal microbiota: a promising direction for prevention and treatment in cervical cancer.Infectious agents and cancer · 2024Review
- Ovarian Cancer and the Microbiome: Connecting the Dots for Early Diagnosis and Therapeutic Innovations-A Review.Medicina (Kaunas, Lithuania) · 2024Review
- Polyphenols Influence the Development of Endometrial Cancer by Modulating the Gut Microbiota.Nutrients · 2024Review
- 2bRAD-M reveals the difference in microbial distribution between cancerous and benign ovarian tissues.Frontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical, ovarian and endometrial cancer are the three most common types of gynecologic cancer. As a hub, the vagina connects the site of gynecological cancer with the external environment. Lactobacilli participate in the formation of a healthy vaginal microenvironment as the first line of defense against pathogen invasion; a dysbiotic vaginal microenvironment loses its original protective function and is associated with the onset, metastasis, poor efficacy and poor prognosis of gynecological cancer. The early diagnosis of cancer is the key to improve the survival time of patients with cancer. The screening of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.